CD85 antigen-like family member J,CD85J,Ig-like transcript 2,ILT2,ILT-2,immunoglobulin heavy chain variable region,Immunoglobulin-like transcript 2,leucocyte Ig-like receptor B1,leukocyte immunoglobulin-like receptor subfamily B member 1,leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1,LIR1,LIR-1,MIR7,MIR-7,monocyte/macrophage immunoglobulin-like receptor 7,myeloid inhibitory receptor 7,PIRB,PIR-B.
Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
